Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB -4.19%71 Days Sales Outstanding is 96.29 as of Jun. 2026, which is 3% below its 10-year median of 99.08. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.52 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 77.22% on this metric.
The historical rank and industry rank for Cytek Biosciences's Days Sales Outstanding or its related term are showing as below:
CTKB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.68 Med: 99.08 Max: 111.49
Current: 97.81
During the past 7 years, Cytek Biosciences's highest Days Sales Outstanding was 111.49. The lowest was 66.68. And the median was 99.08.
CTKB's Days Sales Outstanding is ranked worse than 77.22% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs CTKB: 97.81
Cytek Biosciences's Days Sales Outstanding
declined
from Jun. 2025 (111.32) to Jun. 2026 (96.29).
Cytek Biosciences (NAS:CTKB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cytek Biosciences Days Sales Outstanding Related Terms
Cytek Biosciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, TCMD, CBLL: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Cytek Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Days Sales Outstanding falls into.
Cytek Biosciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Days Sales Outstanding of 96.29 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cytek Biosciences and its competitors. This is near median its historical median of 99.08. Over the past decade, Cytek Biosciences' Days Sales Outstanding has ranged from 66.68 to 111.49. According to the industry distribution chart, Cytek Biosciences ranks #627 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 77.2%.
Is Cytek Biosciences' Days Sales Outstanding too high?
Cytek Biosciences' current Days Sales Outstanding of 96.29 is near median its 10-year median of 99.08. Over the past 10 years, this metric has ranged from a low of 66.68 to a high of 111.49. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Cytek Biosciences' value of 96.29 is 47.8% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #627 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Days Sales Outstanding compare to CERS and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #627 out of 812 companies for Days Sales Outstanding. This places Cytek Biosciences in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. Cytek Biosciences' value of 96.29 is 47.8% above this benchmark. Historically, Cytek Biosciences' own Days Sales Outstanding has ranged from 66.68 to 111.49 over the past decade. While the company's 10-year median is 99.08 vs. the industry median of 65.17, Cytek Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Days Sales Outstanding of 96.29 is 47.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Days Sales Outstanding is 96.29, which is near median its own 10-year median of 99.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.52, compared to a current price of $4.69 — trading 15.1% below its estimated fair value. The current Days Sales Outstanding is 96.29, which is near median its 10-year median of 99.08 and 47.8% above the Medical Devices & Instruments industry median of 65.17. Cytek Biosciences' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Days Sales Outstanding is 96.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.69 is trading 15.1% below its estimated GF Value™ of $5.52.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Days Sales Outstanding: 96.29 (near median its 10-year median of 99.08)
GF Value™: $5.52 vs. price of $4.69 (15.1% below fair value)
Industry Position: 47.8% above the Medical Devices & Instruments median (#627 of 812)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
